ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.55 Million CAD | 75.51% |
| 2022 | -6.34 Million CAD | -4.82% |
| 2021 | -6.05 Million CAD | -31.36% |
| 2020 | -4.6 Million CAD | -62.25% |
| 2019 | -2.84 Million CAD | -18.4% |
| 2018 | -2.39 Million CAD | -18.65% |
| 2017 | -2.02 Million CAD | -79.47% |
| 2016 | -1.12 Million CAD | -21.4% |
| 2015 | -927.88 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -157 Thousand CAD | 65.72% |
| 2024 Q2 | -333 Thousand CAD | -112.1% |
| 2023 Q3 | -784 Thousand CAD | -91.69% |
| 2023 Q1 | 97 Thousand CAD | 104.49% |
| 2023 Q2 | -409 Thousand CAD | -521.65% |
| 2023 Q4 | -458 Thousand CAD | 41.58% |
| 2023 FY | -1.55 Million CAD | 75.51% |
| 2022 Q2 | -1.36 Million CAD | -60.35% |
| 2022 FY | -6.34 Million CAD | -4.82% |
| 2022 Q4 | -2.16 Million CAD | -16.32% |
| 2022 Q3 | -1.85 Million CAD | -36.24% |
| 2022 Q1 | -850 Thousand CAD | 0.23% |
| 2021 Q4 | -852 Thousand CAD | 55.69% |
| 2021 Q1 | -1.24 Million CAD | 2.13% |
| 2021 Q2 | -904 Thousand CAD | 27.16% |
| 2021 Q3 | -1.92 Million CAD | -112.72% |
| 2021 FY | -6.05 Million CAD | -31.36% |
| 2020 Q4 | -1.26 Million CAD | -55.97% |
| 2020 FY | -4.6 Million CAD | -62.25% |
| 2020 Q3 | -813 Thousand CAD | -28.84% |
| 2020 Q1 | -1.06 Million CAD | -122.69% |
| 2020 Q2 | -631 Thousand CAD | 40.47% |
| 2019 FY | -2.84 Million CAD | -18.4% |
| 2019 Q4 | -476 Thousand CAD | 30.71% |
| 2019 Q3 | -687 Thousand CAD | -3.78% |
| 2019 Q2 | -662 Thousand CAD | -12.2% |
| 2019 Q1 | -590 Thousand CAD | 13.85% |
| 2018 Q2 | -483.8 Thousand CAD | -7.04% |
| 2018 Q1 | -451.96 Thousand CAD | 55.06% |
| 2018 Q3 | -778.04 Thousand CAD | -60.82% |
| 2018 Q4 | -684.82 Thousand CAD | 11.98% |
| 2018 FY | -2.39 Million CAD | -18.65% |
| 2017 FY | -2.02 Million CAD | -79.47% |
| 2017 Q1 | -195.55 Thousand CAD | 3.87% |
| 2017 Q2 | -361.94 Thousand CAD | -85.08% |
| 2017 Q3 | -397.15 Thousand CAD | -9.73% |
| 2017 Q4 | -1 Million CAD | -153.24% |
| 2016 Q2 | -360.37 Thousand CAD | -32.15% |
| 2016 FY | -1.12 Million CAD | -21.4% |
| 2016 Q4 | -203.43 Thousand CAD | 29.84% |
| 2016 Q1 | -272.7 Thousand CAD | 59.17% |
| 2016 Q3 | -289.94 Thousand CAD | 19.54% |
| 2015 Q2 | -54.44 Thousand CAD | -48.99% |
| 2015 FY | -927.88 Thousand CAD | 0.0% |
| 2015 Q4 | -667.84 Thousand CAD | -295.05% |
| 2015 Q1 | -36.54 Thousand CAD | 0.0% |
| 2015 Q3 | -169.05 Thousand CAD | -210.5% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -6.78 Million CAD | 77.084% |
| Asep Medical Holdings Inc | -8.22 Million CAD | 81.112% |
| BetterLife Pharma Inc. | -2.88 Million CAD | 46.21% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 79.785% |
| Rapid Dose Therapeutics Corp. | -4.3 Million CAD | 63.915% |
| Defence Therapeutics Inc. | -13.19 Million CAD | 88.221% |
| Entheon Biomedical Corp. | -300 Thousand CAD | -417.998% |
| Gemina Laboratories Ltd. | -5.21 Million CAD | 70.212% |
| Glow Lifetech Corp. | -1.64 Million CAD | 5.567% |
| Lexston Life Sciences Corp. | -867.71 Thousand CAD | -79.091% |
| Pharmala Biotech Holdings Inc. | -779.81 Thousand CAD | -99.279% |
| Doseology Sciences Inc. | -339.84 Thousand CAD | -357.263% |
| MYND Life Sciences Inc. | -1.51 Million CAD | -2.381% |
| Nova Mentis Life Science Corp. | -1.22 Million CAD | -26.917% |
| PharmaTher Holdings Ltd. | -3.11 Million CAD | 50.118% |
| PreveCeutical Medical Inc. | -1.27 Million CAD | -21.933% |
| Telescope Innovations Corp. | -5.72 Million CAD | 72.867% |